KDventures Reports Mixed 2025 Results Amid Portfolio Advances
Event summary
- KDventures reported a net loss of SEK -193.9 million for 2025, with Q4 losses widening to SEK -39.6 million.
- Portfolio company Dilafor secured a US patent for tafoxiparin and signed a licensing deal with Exeltis.
- SVF Vaccines entered a reverse takeover agreement with Novakand Pharma, valuing the deal at SEK 55 million.
- BOOST Pharma raised SEK 34 million in funding and presented positive long-term data for BT-101.
- KDventures completed a rights issue, raising SEK 115.2 million before issue costs.
The big picture
KDventures' 2025 results reflect the challenges of balancing portfolio growth with financial performance. The company's strategic shifts, including the name change and rights issue, aim to strengthen its position in the competitive life sciences investment landscape. The portfolio's advancements in clinical trials and regulatory approvals highlight the potential for long-term value creation, despite near-term financial headwinds.
What we're watching
- Portfolio Performance
- How the dilution effects on PharmNovo and the downturn in Modus Therapeutics' stock price will impact KDventures' overall portfolio value.
- Regulatory Milestones
- The pace at which Dilafor advances tafoxiparin into phase 3 clinical development following the US patent grant.
- Strategic Transactions
- Whether SVF Vaccines' reverse takeover with Novakand Pharma will accelerate the development of its vaccine candidates.
Related topics